An observational study in COVID-19 Pneumonia and ARDS, sponsored by Sciberras, Stephen M.D.. Completed at 1 site in Malta. Open to participants aged 16 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-04-11.
Sponsored by Sciberras, Stephen M.D. · Observational
This study aims to establish whether tocilizumab has any significant effect on procalcitonin levels on patients diagnosed with COVID-19 pneumonia requiring intensive care admission. The effects on other biochemical and clinical markers are also considered.
A retrospective study, involving the first fifty patients treated with tocilizumab for acute deterioration in COVID-19 pneumonia in the Intensive Care Unit (ICU) at Mater Dei Hospital in Malta.
The following parameters will be collected from medical records:
This group will be compared to a control group was chosen from patients admitted to the ICU who were not eligible for tocilizumab treatment, matched to the study group for age, gender, mode of ventilation required and length of stay in ICU.
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
This study's enrollment of 100 is below the median of 268 across 3,208 observational studies indexed under COVID-19.
Browse COVID-19 studies →Sciberras, Stephen M.D. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
COVID-19 patients treated with tocilizumab single dose therapy in ICU
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The first 50 patients admitted to the ITU at Mater Dei Hospital with COVID-19 Pneumonia, to whom tocilizumab was administered
Drug: Tocilizumab
50 patients admitted to ITU at Mater Dei Hospital with COVID-19 Pneumonia, who did not receive Tocilizumab
Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg
Procalcitonin
effect of Tocilizumab on Procalcitonin levels
Time frame: throughout study completion, daily for maximum of 20 days
CRP
effect of Tocilizumab on CRP levels
Time frame: throughout study completion, daily for maximum of 20 days
WCC
effect of Tocilizumab on WCC levels
Time frame: throughout study completion, daily for maximum of 20 days
Neutrophils
effect of Tocilizumab on Neutrophils levels
Time frame: throughout study completion, daily for maximum of 20 days
Lymphocytes
effect of Tocilizumab on Lymphocytes levels
Time frame: throughout study completion, daily for maximum of 20 days
NLR
effect of Tocilizumab on Neutrophil to Lymphocyte ratio
Time frame: throughout study completion, daily for maximum of 20 days
P/F ratio
effect of Tocilizumab on P/F ratio
Time frame: throughout study completion, daily for maximum of 20 days
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sciberras, Stephen M.D.